Aprinoia Therapeutics Inc.   Report issue

For profit Phase 1 Phase 3
Founded: Taipei City Taiwan (2015)

Organization Overview

First Clinical Trial
2019
NCT04141150
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

APRINOIA Therapeutics | Aprinoia Therapeutics Inc. | APRINOIA Therapeutics, LLC

Active Ingredients

Drugs in Phase 3 Trials (1)

apn-1607 (2 trials)

Drugs in Phase 1 Trials (1)

apnmab005 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Cognitive Dysfunction (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2